Stock listing
Translational Development Acquisition Corp.
Selected listing: TDAC · NASDAQ · USD · US
Translational Development Acquisition Corp. (NASDAQ:TDAC), Finance. Latest release Aug 19, 2026: Translational Development Investor Alert: Kahn Swick & Foti…
- Ticker
- NASDAQ:TDAC
- Asset type
- Stock
- Sector
- Finance
- Industry
- Financial Conglomerates
- Exchange
- NASDAQ
- Currency
- USD
About Translational Development Acquisition Corp.
The company focuses on acquiring and developing innovative businesses in the life sciences sector. TDAC aims to leverage its expertise to drive growth and create value for its shareholders.
Latest news from Translational Development Acquisition Corp.
Translational Development Investor Alert: Kahn Swick & Foti, LLC Investigates Translational Development Acquisition Corp. - TDAC
August 19, 2026
ProLogium and Translational Development Acquisition Corp. Announce $50 Million Committed Primary Capital Investment to Support Proposed Business Combination
July 27, 2026
TDAC reports 85% shareholder retention, $156.8M remaining in trust after extension vote
June 23, 2026
Battery maker ProLogium to list on Nasdaq in $3.8 billion SPAC deal
May 27, 2026
Translational Development Acquisition Corp. 1Q 2026: Net income $1.33M, EPS $0.06— 10-Q Summary
May 15, 2026
Research Translational Development Acquisition Corp.
Translational Development Acquisition Corp. company profile
View the public company page for Translational Development Acquisition Corp. on 6ix.
Translational Development Acquisition Corp. news
Read company news and market updates connected to Translational Development Acquisition Corp..
Translational Development Acquisition Corp. investor events
Find investor webinars, events, and replay context for Translational Development Acquisition Corp..